Vertex Pharmaceuticals Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; comparisons are with Q1 2020 unless otherwise noted. Vertex operates in pharmaceuticals, with its commercial business centered on cystic fibrosis (CF) medicines.
Financial performance
Amounts in USD millions, except per-share data and percentages.
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $1,724.3 | $1,515.1 | +14% |
| Operating income | $887.8 | $720.2 | +23% |
| Net income | $653.1 | $602.8 | +8% |
| Diluted EPS | $2.49 | $2.29 | +9% |
| Cash from operations | $921.1 | $815.7 | +$105.4 |
- Revenue mix: Net product revenue was $1,723.3 million. TRIKAFTA/KAFTRIO contributed $1,193.2 million, up 33%; SYMDEKO/SYMKEVI was $125.0 million, down 28%; ORKAMBI was $218.7 million, down 7%; and KALYDECO was $186.3 million, down 12%. Other revenue was $1.0 million.
- Margins and expenses: Operating margin was approximately 51.5%, compared with 47.5% in Q1 2020. Cost of sales was about 11% of product revenue in both periods. R&D was $456.0 million (+2%); SG&A was $192.1 million (+5%). Combined R&D and SG&A rose to $648.1 million from $630.8 million.
- Taxes and non-operating items: The effective tax rate was 20%, versus 8%, and tax expense rose to $167.8 million from $54.8 million. The prior-year rate benefited from a discrete tax benefit not repeated in 2021. Other expense, net, was $52.7 million, primarily reflecting losses on strategic equity investments; interest income fell to $1.5 million from $12.6 million.
- Cash flow and investment: Operating cash flow was $921.1 million. Property and equipment purchases were $70.9 million; operating cash flow less these purchases was approximately $850.1 million. Financing cash outflow was $518.7 million, including $425.0 million of share repurchases.
- Liquidity and obligations: Cash, cash equivalents and marketable securities totaled $6,924.0 million at March 31, up $265.1 million from year-end. Working capital was $6,595.3 million. Vertex reported $530.3 million of long-term finance lease liabilities and $368.5 million of long-term operating lease liabilities. Its $2.5 billion revolving credit facilities were undrawn; the company reported compliance with their covenants.
Material changes and business developments
- Revenue growth was driven principally by KAFTRIO uptake in Europe and continued TRIKAFTA performance in the U.S.; other CF products declined mainly as patients switched to the triple-combination regimen. Ex-U.S. product revenue increased to $469.9 million from $327.5 million.
- Development expense increased 12%, reflecting investment in the expanding pipeline, including clinical trials, headcount and infrastructure. Research expense declined 17%, largely because collaboration payments were $1.7 million versus $36.3 million in the prior-year quarter.
- Vertex repurchased 1.99 million shares for $424.9 million in Q1, completing the $500 million authorization under its 2020 repurchase program.
- After quarter-end, Vertex amended its CTX001 collaboration with CRISPR Therapeutics, subject to closing conditions. Vertex expects to pay $900 million at closing, recorded as R&D expense, and a further $200 million upon first FDA or European Commission marketing approval. CTX001 profits and losses are to be allocated 60% to Vertex and 40% to CRISPR under the revised terms.
Outlook, risks and unusual items
- The filing provides no clear full-year revenue or earnings guidance. Management expects existing liquidity and product cash flows to fund operations for at least 12 months and does not expect COVID-19 to adversely affect liquidity. It reported no COVID-19 impact on supply or medicine demand at the time of filing.
- Management cited expected CF-business growth through expanded eligibility and access. Pipeline milestones included expected VX-864 Phase 2 results in Q2 2021, VX-147 results in the second half of 2021, and planned advancement of VX-548 into Phase 2 acute-pain studies in the second half of 2021. CTX001 enrollment was ongoing, with enrollment completion expected in 2021.
- Key risks include clinical and regulatory uncertainty, reimbursement and market access, and the possibility that development timelines or trial outcomes differ from expectations. Management noted strategic investment valuations may fluctuate and materially affect quarterly or annual earnings. The $900 million CRISPR payment depends on transaction closing; the additional $200 million depends on regulatory approval.
- No material legal proceedings or material accrued contingent liabilities were reported. The filing stated there were no material changes to the risk factors previously disclosed in the 2020 Form 10-K. The fair value of Exonics contingent consideration decreased $3.9 million in Q1; management warned estimates could change and adjustments could be material.
Important facts for investors to verify
- Whether the CRISPR transaction closed, when the $900 million payment was recorded, and how the revised CTX001 economics affect future R&D expense and cash flows.
- Whether TRIKAFTA/KAFTRIO growth and international reimbursement continue to offset declines in the older CF products.
- Progress and results from the cited pipeline trials, particularly CTX001, VX-864 and VX-147, against management’s stated timelines.
- The effect of strategic equity investment volatility and changes in the effective tax rate on reported earnings.
- Future operating cash flow, capital spending, share repurchases and lease commitments; the filing does not provide a separate total for all current and long-term debt obligations.